Every day, the world's scientists and researchers are working to improve human health, develop medical knowledge, and find cures and treatments to improve outcomes for patients. Here are three key medical breakthroughs from this year.
Bespoke drugs for Alzheimer's patients A Dutch study raised hopes that Alzheimer's treatment could become much more personalised. The researchers identified five "molecular subtypes" of the disease that each have "clear differences" in their genetics and in "the clinical characteristics" that patients display, said Live Science. The team were able to sort more than 400 Alzheimer's patients into these five subtypes, according to the different "levels of specific proteins in their cerebrospinal fluid", a clear liquid that flows around the brain and spinal cord. It is these proteins that are associated with the biological processes that "get derailed in Alzheimer's". The study findings are an "important step" towards being able to give each Alzheimer's patient "the best drug for them at the right stage of their disease".
'Gamechanger' for asthma and lung disease Doctors are hailing a new treatment for asthma and chronic obstructive pulmonary disease (COPD) attacks as "the first breakthrough for 50 years". It could be a "gamechanger", said The Guardian. In a trial outlined in The Lancet Respiratory Medicine, respiratory medicine specialists found that a single, high-dose injection of benralizumab was more effective than the current steroid-tablets treatment at managing the type of flare-up behind 50% of asthma attacks and 30% of COPD attacks. The injection also cut "the need for further treatment by 30%". Benralizumab is already used, at a low dose, as a repeat treatment for severe asthma, but the trial results could be "transformative for millions of people with asthma and COPD around the world".
Personalised cancer vaccines Patients in England being treated for cancer are taking part in NHS trials of a "world-first" personalised cancer vaccine. The mRNA vaccine is "custom-built" for each eligible patient and works "by training the immune system to recognise, destroy and prevent the spread of cancer cells", said NHS England. The trials are running at 30 sites across England in partnership with research company BioNTech, and are initially focusing on patients with colorectal, skin, lung, bladder, pancreatic and kidney cancer. |